Erika Hamilton/LinkedIn
May 31, 2025, 03:01
Erika Hamilton: What Will We See at ASCO25 Breast Cancer Rapid Oral?
Erika Hamilton, Chair of Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“What will we see at today’s ASCO25 Breast Cancer rapid oral?
Hall D2, 2:45-4:15pm CST
– TDXd Drug rechallenge after ILD
– sac-TMT 1st L TNBC – OptiTROP-Br05
– AI for pathologic assessment of HER-2
– Kat-6 inhibitor for ER+ MBC
– PI3 (gedatolisib) + trastuzumab for HER-2
– 2 abstracts around efficacy in brain metastasis
…and more.”
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 09:31
Jun 8, 2025, 09:15
Jun 8, 2025, 08:43